Form 4 for VIR Vir Biotechnology, Inc.
Accepted 2022-01-26 00:00:00 ET · period of report 2022-01-25 · accession 0001209191-22-005117 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-26 | 2022-01-25 | VIR | Virgin Herbert | EVP, CSO, Research | S - Sale+OE | $32.46 | -1,375 | 107.7K | -1% | -$44.6K |
| D | 2022-01-26 | 2022-01-25 | VIR | Virgin Herbert | EVP, CSO, Research | M - OptEx | $1.53 | +1,375 | 109.1K | +1% | +$2,104 |
| D | 2022-01-26 | 2022-01-25 | VIR | Virgin Herbert | EVP, CSO, Research | M - OptEx | $0.00 | -1,375 | 222.3K | -0.6% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-25 | S | D | 1,375 | $32.46 | 107,700 | D | — | — | |
| 2 | Common | Common Stock | 2022-01-25 | M | A | 1,375 | $1.53 | 109,075 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-01-25 | M | D | 1,375 | $0.00 | 222,255 | D | $1.53 · — to 2028-01-26 | 1,375 Common Stock | (F2) The option is fully vested and exercisable. |